The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Immune dysregulation in ITP and warm AIHA
Alessandro Lucchesi, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the role of chronic inflammation and immune dysregulation in immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). He highlights emerging therapeutic strategies targeting the inflammasome, BTK, and SYK pathways, and explains how these agents may improve outcomes beyond conventional antibody-directed therapies. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
